BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced that it will host a virtual Bardet-Biedl Syndrome (BBS) event to discuss the patient experience, key opinion leaders’ perspectives, and the Company’s U.S. commercialization plans to address the severe obesity and hyperphagia that characterize this condition.

Caladrius Biosciences, Inc. announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022.

Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of its initial public offering of 9,487,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that the company will report fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022.

Movmedix, formerly L.A.R.S., an SME based in Arc-sur-Tille, close to Dijon, is the international leader in artificial ligament with more than 8.5 million euros sales worldwide in 2021, and a growth rate of more than 60%.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

The Board of Directors of Zoetis Inc. has declared a dividend of $0.325 per share for the second quarter of 2022.